Scott E. Warder
AbbVie (United States)(US)BC Platforms (Finland)(FI)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Ubiquitin and proteasome pathways, Chemical Synthesis and Analysis
Most-Cited Works
- → Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor(2017)134 cited
- → Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies(2017)118 cited
- → CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16(2023)75 cited
- → Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners’ Perspective(2018)67 cited
- → Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors(2017)64 cited
- → Reducing agent-mediated precipitation of high-abundance plasma proteins(2009)64 cited